Current Treatment Options in Oncology

, Volume 7, Issue 6, pp 438–443 | Cite as

The enigma of desmoid tumors

  • Scott Okuno

Opinion statement

Desmoid tumors (aggressive fibromatosis) are rare neoplastic tumors that may occur sporadically or in association with familial adenomatous polyposis (FAP). The etiology of these tumors is unknown, but hormonal, genetic, and physical factors play a role in their development and growth. A distinction is often made between desmoids in patients with FAP and those in patients without FAP, but clinically these tumors are treated the same; the only difference is the preferential intra-abdominal location of FAP desmoids. The goal of desmoid treatment is local control. Choosing the appropriate method for achieving local control may be complex as the functional and cosmetic outcomes of each method must be considered. In addition, because desmoids spontaneously regress, any claim of successful intervention must be viewed skeptically. Local control is mainly achieved by surgical intervention and may be improved with the addition of radiation therapy (RT). For patients who cannot undergo surgery, the options for local control include RT and systemic therapies such as hormones, nonsteroidal anti-inflammatory drugs (NSAIDs), interferon, and chemotherapy. Patients with symptomatic, progressive disease who can tolerate chemotherapy should be presented with the option of low-dose or standard antisarcoma chemotherapy. Although it is unclear which regimen is better, patients appear to have quicker responses to the standard antisarcoma therapy. Hormone therapy, NSAIDs, and interferon are used often, with varying success, and should be reserved for minimally symptomatic patients or for patients who do not want or are not candidates for chemotherapy. The treatment of desmoid tumors remains an enigma. As more options become available, selecting the correct therapy becomes more nuanced. Further clinical trials are needed to help the clinician navigate his or her way through the morass of desmoid tumor therapies.


Imatinib Local Control Familial Adenomatous Polyposis Adenomatous Polyposis Coli Sulindac 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Zlotecki RA, Scarborough MT, Morris CG, et al.:External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys 2002, 54:177–181. Good report on the role of radiation alone in desmoid tumors.PubMedCrossRefGoogle Scholar
  2. 2.
    Bertario L, Russo A, Sala P, et al.:Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 2001, 95:102–107.PubMedCrossRefGoogle Scholar
  3. 3.
    Goldblum J, Fletcher JA:Desmoid-type fibromatoses. In World Health Organization Classification of Tumors. Edited by Fletcher CD, Unni KK, Mertens F. Lyon, France:International Agency for Research on Cancer (IARC); 2002:83–84.Google Scholar
  4. 4.
    Cheon SS, Cheah AY, Turley S, et al.:beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S A 2002, 99:6973–6978.PubMedCrossRefGoogle Scholar
  5. 5.
    Tejpar S, Michils G, Denys H, et al.:Analysis of Wnt/beta catenin signalling in desmoid tumors. Acta Gastroenterol Belg 2005, 68:5–9.PubMedGoogle Scholar
  6. 6.
    Tejpar S, Li C, Yu C, et al.:Tcf-3 expression and betacatenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour). Br J Cancer 2001, 85:98–101.PubMedCrossRefGoogle Scholar
  7. 7.
    Mendenhall WM, Zlotecki RA, Morris CG, et al.:Aggressive fibromatosis. Am J Clin Oncol 2005, 28:211–215.PubMedCrossRefGoogle Scholar
  8. 8.
    Leithner A, Gapp M, Radl R, et al.:Immunohistochemical analysis of desmoid tumours. J Clin Pathol 2005, 58:1152–1156.PubMedCrossRefGoogle Scholar
  9. 9.
    Nuyttens JJ, Rust PF, Thomas CR Jr, Turrisi AT 3rd:Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors:a comparative review of 22 articles. Cancer 2000, 88:1517–1523. Excellent summary on the role of surgery with or without RT.PubMedCrossRefGoogle Scholar
  10. 10.
    Waddell WR, Gerner RE:Indomethacin and ascorbate inhibit desmoid tumors. J Surg Oncol 1980, 15:85–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Hansmann A, Adolph C, Vogel T, et al.:High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004, 100:612–620.PubMedCrossRefGoogle Scholar
  12. 12.
    Wilcken N, Tattersall MH:Endocrine therapy for desmoid tumors. Cancer 1991, 68:1384–1388.PubMedCrossRefGoogle Scholar
  13. 13.
    Raguse JD, Gath HJ, Oettle H, Bier J:Interferon-induced remission of rapidly growing aggressive fibromatosis in the temporal fossa. Int J Oral Maxillofac Surg 2004, 33:606–609.PubMedCrossRefGoogle Scholar
  14. 14.
    Leithner A, Schnack B, Katterschafka T, et al.:Treatment of extra-abdominal desmoid tumors with interferonalpha with or without tretinoin. J Surg Oncol 2000, 73:21–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Okuno SH, Edmonson JH:Combination chemotherapy for desmoid tumors. Cancer 2003, 97:1134–1135.PubMedCrossRefGoogle Scholar
  16. 16.
    Patel SR, Evans HL, Benjamin RS:Combination chemotherapy in adult desmoid tumors. Cancer 1993, 72:3244–3247.PubMedCrossRefGoogle Scholar
  17. 17.
    Weiss AJ, Horowitz S, Lackman RD:Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol 1999, 22:193–195. Initial report on the value of low-dose chemotherapy in the treatment of desmoid tumors.PubMedCrossRefGoogle Scholar
  18. 18.
    Azzarelli A, Gronchi A, Bertulli R, et al.:Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001, 92:1259–1264.PubMedCrossRefGoogle Scholar
  19. 19.
    Lynch HT, Fitzgibbons R Jr, Chong S, et al.:Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum 1994, 37:260–267.PubMedCrossRefGoogle Scholar
  20. 20.
    Gega M, Yanagi H, Yoshikawa R, et al.:Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006, 24:102–105. Current study on the role of doxorubicin and dacarbazine in desmoid tumors.PubMedCrossRefGoogle Scholar
  21. 21.
    Mace J, Sybil Biermann J, Sondak V, et al.:Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002, 95:2373–2379.PubMedCrossRefGoogle Scholar
  22. 22.
    Heinrich MC, McArthur GA, Demetri GD, et al.:Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006, 24:1195–1203. Up-to-date study defining the role of imatinib in desmoid tumors and exploring imatinib's mechanism of action.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Scott Okuno
    • 1
  1. 1.Medical OncologyMayo ClinicRochesterUSA

Personalised recommendations